InsidersTradesSigma
Track the Arrowhead Pharmaceuticals Inc. stock price and the full directors' dealings record of the company, a listed equity based in United States. Shares are listed on the US market, under the authority of SEC (Form 4). Market capitalisation: €12bn. The latest transaction was disclosed on 18 August 2026 (Notice of proposed sale (Form 144)). Among the most active insiders: Michael Perry. The full history is free.
Analysts rate Arrowhead Pharmaceuticals Inc. Strong Buy (bullish), based on 11 analysts. Average price target: US$110.18.
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
2 of 2 declarations
Arrowhead Pharmaceuticals Inc. is a biopharmaceutical company focused on developing RNA-based therapies to treat genetic and viral diseases. It is listed on NASDAQ under the ticker ARWR.